The Paper | Combined Q1 Revenue of 111 Pharmaceutical Companies on the Main Board of the SSE Exceeds RMB 330.5 Billion

Data shows that 111 pharmaceutical companies on the main board of the Shanghai Stock Exchange (SSE) achieved a total operating revenue of RMB 330.55 billion in Q1 2026, with a year-on-year increase of 2%. Their combined net profit reached RMB 24.7 billion, with a year-on-year increase of 0.5%.

Among them, WuXi AppTec and Hengrui Pharmaceuticals contributed net profits of over RMB 4.65 billion and RMB 2.28 billion, respectively. Both companies recorded significant growth in both revenue and net profit for Q1, providing strong support to the industry's Q1 performance. (Pengpai News Journalist: Tian Zhongfang)